ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1119

Association of Primary Insurance Status on Bilateral Knee Arthroplasty Utilization and Complications: A United States Nationwide Analysis
Abstract Number: 1120

A Comparison of Opioid-Related Outcomes Among Commercially-Insured Osteoarthritis Patients Treated with Tramadol vs. Non-Tramadol Opioids
Abstract Number: 1121

Osteoarthritis in the Million Veterans Program: Integrating the Electronic Medical Record with Precision Medicine
Abstract Number: 1122

Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review
Abstract Number: 1123

The Patient Journey in Knee OA: Variations in Patient Characteristics and Treatment by Physician Specialty
Abstract Number: 1124

Improving Documentation Rates of Non-Pharmacologic Therapies for Knee Osteoarthritis
Abstract Number: 1125

Patient Reported Impact of Lupus on Quality of Life
Abstract Number: 1126

A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study
Abstract Number: 1127

Association of Health Literacy and Numeracy with Patient Reported Psychological Outcomes
Abstract Number: 1128

The Diagnosis of Systemic Sclerosis as a Traumatic Experience: Patients’ Reactions to the Diagnostic Process
Abstract Number: 1129

Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis
Abstract Number: 1130

Patient Perspectives on Biobanking and Data-linkage for Rheumatic Disease Research
Abstract Number: 1131

Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Abstract Number: 1132

Reliability of Virtual Sources of Education for Patients with Vasculitis
Abstract Number: 1133

Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Disease Understanding and Participation in Research Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].